Fetal/neonatal alloimmune thrombocytopenias;Les thrombopénies fœtales et néonatales allo-immunes

Transfusion Clinique et Biologique

Volumn 16, Issue 2, 2009, Pages 214-217

  Kaplan, C ^a  

^a INSTITUT NATIONAL DE LA TRANSFUSION SANGUINE   (France)

Author keywords

Alloimmunization; Fetus; Neonate; Thrombocytopenia

Indexed keywords

ALLOANTIBODY; IMMUNOGLOBULIN G; PREDNISONE; THROMBOCYTE ANTIGEN;

ANTIBODY DETECTION; BRAIN HEMORRHAGE; DEATH; FATHER; HUMAN; IMMUNIZATION; LABORATORY DIAGNOSIS; LIVE BIRTH; MORBIDITY; MOTHER; NEONATAL ALLOIMMUNE THROMBOCYTOPENIA; SHORT SURVEY; ARTICLE; BLOOD; FEMALE; FETUS DISEASE; IMMUNOLOGY; NEWBORN; PREGNANCY; PREGNANCY COMPLICATION; THROMBOCYTE;

BLOOD PLATELETS; FEMALE; FETAL DISEASES; HUMANS; INFANT, NEWBORN; PREGNANCY; PREGNANCY COMPLICATIONS; THROMBOCYTOPENIA, NEONATAL ALLOIMMUNE;

EID: 67349276173     PISSN: 12467820     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tracli.2009.03.013     Document Type: Short Survey

References (36)

1. Hohlfeld P., Forestier F., Kaplan C., Tissot J.D., and Daffos F. Diagnosis and management of foetal thrombocytopenia. Nouv Rev Fr Hematol 35 (1993) 413-418
2. Dreyfus M., Kaplan C., Verdy E., Schlegel N., Durand-Zaleski I., and Tchernia G. Frequency of immune thrombocytopenia in newborns: a prospective study. Blood 89 (1997) 4402-4406
3. Mueller-Eckhardt C., Kiefel V., Grubert A., Kroll H., Weisheit M., Schmidt S., et al. 348 cases of suspected neonatal alloimmune thrombocytopenia. Lancet 1 (1989) 363-366
4. Durand-Zaleski I., Schlegel N., Blum-Boisgard C., Uzan S., Dreyfus M., and Kaplan C. Screening primiparous women and newborns for fetal/neonatal alloimmune thrombocytopenia: a prospective comparison of effectiveness and costs. Am J Perinatol 13 (1996) 423-431
5. Metcalfe P., Watkins N.A., Ouwehand W.H., Kaplan C., Newman P., Kekomaki R., et al. Nomenclature of human platelet antigens. Vox Sang 85 (2003) 240-245
6. Kaplan C., Patereau C., Reznikoff-Etievant M.F., Muller J.Y., Dumez Y., and Kesseler A. Antenatal PLA1 typing and detection of GP IIb-IIIa complex. Br J Haematol 60 (1985) 586-588
7. a) neonatal alloimmune thrombocytopenia: clinical and immunological analysis of 39 cases. Br J Haematol 78 (1991) 425-429
8. Glade-Bender J., McFarland J.G., Kaplan C., Porcelijn L., and Bussel J.B. Anti-HPA-3a induces severe neonatal alloimmune thrombocytopenia. J Pediatr 138 (2001) 862-867
9. a) is an important cause of neonatal alloimmune thrombocytopenia. Transfusion 45 (2005) 1487-1495
10. a) feto-maternal alloimmunization, a clinically severe neonatal thrombocytopenia: difficulties in diagnosis and therapy, report on 8 families. Transfusion 45 (2005) 1799-1803
11. Bertrand G., Bianchi F., Alexandre M., Quesne J., Chenet C., Martageix C., et al. HPA-13bw neonatal alloimmune thrombocytopenia and low frequency alloantigens: case report and review of the literature. Transfusion 47 (2007) 1510-1513
12. Valentin N., Vergracht A., Bignon J.D., Cheneau M.L., Blanchard D., Kaplan C., et al. HLA-DRw52a is involved in alloimmunization against PL-A1 antigen. Hum Immunol 27 (1990) 73-79
13. A1) is strongly associated with both HLA-DR3*0101 and HLA-DQB1*0201. Hum Immunol 34 (1992) 107-114
14. Kuijpers R.W.A.M., von dem Borne AEGKr, Kiefel V., Eckhardt C.M., Waters A.H., Zupanska B., et al. Leucine33-proline33 substitution in human platelet glycoprotein IIIa determines HLA-DRw52a (Dw24) association of the immune response against HPA-1a (Zwa/PlA1) and HPA-1b (Zwb/PlA2). Hum Immunol 34 (1992) 253-256
15. Wu S., Maslanka K., and Gorski J. An integrin polymorphism that defines reactivity with alloantibodies generates an anchor for MHC class II peptide binding: a model for unidirectional alloimmune responses. J Immunol 158 (1997) 3221-3226
16. Ahlen MT, Husebekk A, Killie MK, Skogen B, Stuge TB. T cell responses associated with neonatal alloimmune thrombocytopenia: isolation of HPA-1a-specific, HLA-DRB3*010-restricted CD4* T cells. Blood 2009; doi:10.1182/blood-2008-09-178475.
17. Semana G., Zazoun T., Alizadeh M., Morel-Kopp M.C., Genetet B., Kaplan C., et al. Genetic susceptibility and anti-human platelet antigen 5b alloimmunization. Role of HLA class II and TAP genes. Hum Immunol 46 (1996) 114-119
18. Spencer J.A., and Burrows R.F. Feto-maternal alloimmune thrombocytopenia: a literature review and statistical analysis. Aust N Z J Obstet Gynaecol 41 (2001) 45-55
19. Kaplan C., Dreyfus M., Proulle V., and Tchernia G. Thrombocytopenia in childhood. In: Gresele P., Page C.P., Vermylen J., and Fuster V. (Eds). Platelets in thrombotic and non-thrombotic disorders: pathophysiology, pharmacology and therapeutics (2002), Cambridge University Press, Cambridge 556-568
20. Kroll H., Kiefel V., and Santoso S. Clinical aspects and typing of platelet alloantigens. Vox Sang 74 (1998) 345-354
21. Kiefel V., Santoso S., Weisheit M., and Mueller-Eckhardt C. Monoclonal antibody-specific immobilization of platelet antigens (MAIPA): a new tool for the identification of platelet-reactive antibodies. Blood 70 (1987) 1722-1726
22. Morel-Kopp M.C., Daviet L., McGregor J., and Kaplan C. Drawbacks of the MAIPA technique in characterising human antiplatelet antibodies. Blood Coagul Fibrinolysis 7 (1996) 144-146
23. Harrison C.R., Curtis B.R., McFarland J.G., Huff R.W., and Aster R.H. Severe neonatal alloimmune thrombocytopenia caused by antibodies to human platelet antigen 3a (Baka) detectable only in whole platelet assays. Transfusion 43 (2003) 1398-1402
24. Bertrand G., Bianchi F., Chenet C., Martageix C., Blanchet P., Bäumler M., et al. New mutation in the platelet β3-integrin gene: implication for the diagnosis of fetomaternal alloimmunization. Transfusion 46 (2006) 2138-2141
25. 3-integrin gene is not restricted to a single family. Transfusion 48 (2008) 402
26. Jallu V., Bianchi F., and Kaplan C. Fetal-neonatal alloimmune thrombocytopenia and unexpected Glanzmann thrombasthenia carrier: report of two cases. Transfusion 45 (2005) 550-553
27. Halle L., Jallu V., Mulen-Imandy G., Bigot A., M'bayo K., Anani L.Y., et al. New mutations on platelet GPIIb in Sub Saharan African populations revealed by genotyping discrepancies. Transfusion 48 (2008) 1415-1422
28. Kiefel V., Bassler D., Kroll H., Paes B., Giers G., Ditomasso J., et al. Antigen-positive platelet transfusion in neonatal alloimmune thrombocytopenia (NAIT). Blood 107 (2006) 3761-3763
29. Bussel J.B., McFarland J.G., and Berkowitz R.L. Antenatal management of fetal alloimmune and autoimmune thrombocytopenia. Transfus Med Rev (1990) 149-162
30. Kaplan C., Murphy M., Kroll H., and Waters A.H. Antenatal therapy with IVIgG and steroids for feto-maternal alloimmune thrombocytopenia: report of the European experience [abstract]. Thromb Haemost 73 (1995) 1529
31. Birchall J.E., Murphy M.F., Kaplan C., Kroll H., and on behalf of the European fetomaternal alloimmune thrombocytopenia study group. European collaborative study of the antenatal management of feto-maternal alloimmune thrombocytopenia. Br J Haematol 122 (2003) 275-288
32. Kanhai H.H.H., Porcelijn L., Engelfriet C.P., Reesink H.W., Panzer S., Ulm B., et al. Management of alloimmune thrombocytopenia. Vox Sang 93 (2007) 370-385
33. Bertrand G., Martageix C., Jallu V., Vitry F., and Kaplan C. Predictive value of sequential maternal anti-HPA-1a antibody concentrations for the severity of fetal alloimmune thrombocytopenia. J Thromb Haemost 4 (2006) 628-637
34. Kanhai H.H.H., van den Akker E.S.A., Walther F.J., and Brand A. Intravenous immunoglobulins without initial and follow-up cordocentesis in alloimmune fetal and neonatal thrombocytopenia at high risk for intracranial hemorrhage. Fetal Diagn Ther 21 (2006) 55-60
35. Kjeldsen-Kragh J., Killie M.K., Tomter G., Golebiowska E., Randen I., Hauge R., et al. A screening and intervention program aimed to reduce mortality and serious morbidity associated with severe neonatal alloimmune thrombocytopenia. Blood 110 (2007) 833-839
36. Ghevaert C., Wilcox D.A., Fang J., Armour K.L., Clark M.R., Ouwehand W.H., et al. Developing recombinant HPA-1a-specific antibodies with abrogated Fcγ receptor binding for the treatment of fetomaternal alloimmune thrombocytopenia. J Clin Invest 118 (2008) 2929-2938